Protocol Ledger

NCT07491445 · Phase III · RECRUITING

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Interventional Phase III clinical trial protocol NCT07491445 sponsored by Revolution Medicines in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-09 Enrollment: 900 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07491445
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)900 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07491445
Protocol FieldVerified Registry Value
NCT IdentifierNCT07491445
Consolidated Lead SponsorRevolution Medicines
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment900 participants (ESTIMATED)
Registered Start Date2026-03-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI